[Research progress of mechanisms through which dipeptidyl peptidase-4 inhibitors regulate glycemia].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
; 35(2): 229-33, 2013 Apr.
Article
en Zh
| MEDLINE
| ID: mdl-23643015
ABSTRACT
Dipeptidyl peptidase-4 (DPP-4) inhibitors are promising new antidiabetic drugs. It had been proposed that DPP-4 inhibitors exert their antidiabetic effect by inhibiting the degradation of glucagon-like peptide 1(GLP-1) . However, new evidence has shown that the increase of GLP-1 is not notable after the use of these drugs in patients with type 2 diabetes. Therefore, the specific mechanisms via which DPP-4 inhibitors in controlling blood glucose has became questionable. In recent years, studies have revealed many possible mechanisms through which DPP-4 inhibitors regulate glycemia DPP-4 inhibitors may selectively reduce DPP-4 activity in the intestine, causing the increase of portal plasma GLP-1 level and thus promoting the release of insulin via nerve reflex;also, they may decrease the cleavage product of GLP-1 and reduce the degradation of other bioactive peptides.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Diabetes Mellitus Tipo 2
/
Péptido 1 Similar al Glucagón
/
Inhibidores de la Dipeptidil-Peptidasa IV
/
Hipoglucemiantes
Límite:
Humans
Idioma:
Zh
Revista:
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
Año:
2013
Tipo del documento:
Article
País de afiliación:
China